The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Concurrent thoracic radiotherapy (TRT), platinum/etoposide chemotherapy, and durvalumab immunotherapy in extensive-stage (ES) small cell lung cancer (SCLC): A phase III trial.
 
Bjorn Gronberg
Employment - Lilly (I)
Stock and Other Ownership Interests - Lilly (I)
Honoraria - Accord Healthcare; AstraZeneca; BMS Norway; Gilead Sciences; Immedica; Johnson & Johnson/Janssen; Lilly; MSD; Pfizer; Pharmacosmos
Consulting or Advisory Role - Accord Healthcare; AstraZeneca; Janssen; MSD; Pharmacosmos
Research Funding - AstraZeneca (Inst); Roche (Inst)
 
Daphne Dumoulin
Consulting or Advisory Role - Accord Healthcare (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squib; Bristol-Myers Squibb (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
 
Kersti Oselin
Consulting or Advisory Role - MSD
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - MSD
 
Luigi De Petris
Honoraria - Johnson & Johnson (Inst); MSD (Inst); Pierre Fabre (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); BMS GmbH & Co. KG (Inst); Johnson & Johnson (Inst); Pfizer (Inst)
 
Kirill Neumann
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD
 
Tesfaye Madebo
No Relationships to Disclose
 
Marianne Aanerud
Honoraria - AstraZeneca; BMS Norway
 
Tarje Halvorsen
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; Johnson & Johnson/Janssen; MSD Oncology; Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Immedica; Immedica; MSD Oncology; Sanofi; Sanofi
Research Funding - AstraZeneca (Inst); MSD (Inst); Roche (Inst)
 
Johan Isaksson
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); BMS GmbH & Co. KG (Inst); Johnson & Johnson (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
 
Maria Bjaanæs
No Relationships to Disclose
 
Daniel Heinrich
Stock and Other Ownership Interests - Ultimovacs
Honoraria - Bayer; Ipsen; Pfizer
Research Funding - AstraZeneca (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - IPSEN
 
Odd Terje Brustugun
Honoraria - Amgen (Inst); AstraZeneca (Inst); BMS Norway (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); MSD (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS Norway (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Atle Totland
No Relationships to Disclose
 
Siv Gyda Aanes
Honoraria - Novartis; Pfizer
 
Øyvind Yksnøy
No Relationships to Disclose
 
Andreas Hallqvist
Research Funding - AstraZeneca (Inst)
 
Orvar Gunnarsson
No Relationships to Disclose
 
Terje Skraastad
Honoraria - AstraZeneca; Chiesi; Pfizer
 
Emelie Gezelius
No Relationships to Disclose
 
Kristin Killingberg
No Relationships to Disclose